About
Drug Delivery, Timing
Areas of Focus
Categories
Drug Delivery & FormulationBoston & New England
Team (7)
Anthony H
Anthony H. Cincotta, PhD
Veroscience
team_member
Bindu Chamarthi
Bindu Chamarthi, MD, MMSc
Veroscience
team_member
Carl Richard Stoelzel
Carl Richard Stoelzel, Ph.D.
Veroscience
team_member
Emilie Duvallet
Emilie Duvallet, PhD
Veroscience
team_member
Michael Ezrokhi
Michael Ezrokhi, PhD
Veroscience
team_member
Shuqin Luo
Shuqin Luo, PhD, MD
Veroscience
team_member
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
3
As Collaborator
1
Total Enrollment
3,202
By Phase
PHASE4: 1PHASE1: 1PHASE3: 2
By Status
COMPLETED: 3TERMINATED: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
Today
Hover over trial bars to see details
Recent Trials
NCT02299050Collaborator
Effect of Cycloset on Glycemic Control When Added to Glucagon-like Peptide 1 (GLP-1) Analogue Therapy
PHASE4Completed
23 participants
Started: Jun 30, 2014 · Completed: Apr 30, 2018
NCT02078440Lead Sponsor
Pharmacokinetic Study of CYCLOSET ® 0.8 mg Tablets in Children and Adolescent Type 2 Diabetes Mellitus Subjects
PHASE1Completed
18 participants
Started: Jan 31, 2014 · Completed: Jun 30, 2016
NCT00441363Lead Sponsor
Efficacy and Safety of Cycloset® Compared With Placebo When Added to Metformin
PHASE3Terminated
66 participants
Started: Feb 28, 2005 · Completed: Mar 31, 2006
NCT00377676Lead Sponsor
Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes
PHASE3Completed
3,095 participants
Started: Jul 31, 2004 · Completed: Jan 31, 2007
Locations (1)
Headquarters
Tiverton, RI, United States
Map
Loading map...